ARQT - Arcutis jumps after positive late-stage data in plaque psoriasis

Arcutis Biotherapeutics (ARQT) has surged ~21.9% after the company announced the positive data from two pivotal Phase 3 studies evaluating roflumilast cream (ARQ-151) in plaque psoriasis.The DERMIS-1 and DERMIS-2 trials were identical Phase 3 randomized, parallel, double-blind, vehicle-controlled, multi-national, multi-center studies where roflumilast 0.3% cream or matching vehicle cream were applied once daily for 8 weeks to subjects aged 2 years and above.881 subjects in the trials with mild, moderate, or severe chronic plaque psoriasis involving 2% - 20% body surface area had no treatment-related serious adverse events, the company said, adding that 90% of patients completed the full course of treatment.The once-daily topical formulation of roflumilast, a selective phosphodiesterase type 4 inhibitor, was generally safe and well-tolerated.The primary endpoint of IGA (Investigator Global Assessment) Success rate, defined as IGA score of clear or almost clear and at least a 2-grade improvement from baseline, stood 42.4% in DERMIS-1 after eight weeks compared to

For further details see:

Arcutis jumps after positive late-stage data in plaque psoriasis